- Dissecting depression symptoms:
- <sup>2</sup> multi-omics clustering uncovers
- <sup>3</sup> immune-related subgroups and cell-
- 4 type specific dysregulation
- 5 Jonas Hagenberg<sup>a, b, c</sup> jonas\_hagenberg@psych.mpg.de,
- 6 BeCOME study group<sup>a</sup>,
- 7 OPTIMA study group<sup>a</sup>,
- 8 Tanja M. Brückl<sup>a</sup> brueckl@psych.mpg.de,
- 9 Mira Erhart<sup>a, b</sup> mira\_erhart@psych.mpg.de,
- 10 Johannes Kopf-Beck<sup>a, d</sup> Kopf-Beck@psy.lmu.de,
- 11 Maik Ködel<sup>a</sup> koedel@psych.mpg.de,
- 12 Ghalia Rehawi<sup>a, c</sup> ghalia\_rehawi@psych.mpg.de,
- 13 Simone Röh-Karamihalev<sup>a</sup> simone\_roeh@psych.mpg.de,
- 14 Susann Sauer<sup>a</sup> sauer@psych.mpg.de,
- 15 Natan Yusupov<sup>a, b</sup> natan\_yusupov@psych.mpg.de,
- 16 Monika Rex-Haffner<sup>a</sup> rexhaffner@psych.mpg.de,
- 17 Victor I. Spoormaker<sup>a</sup> spoormaker@psych.mpg.de,
- 18 Philipp Sämann<sup>a</sup> saemann@psych.mpg.de,
- 19 Elisabeth Binder<sup>a, e</sup> binder@psych.mpg.de,
- 20 Janine Knauer-Arloth<sup>a, c, #</sup>arloth@psych.mpg.de
- 21
- 22 a Max His peptiki Institute of Baschharty of reepelinstry 2-10, 80804 Muniche Germany clinical practice.

- 23 b International Max Planck Research School for Translational Psychiatry, 80804 Munich,
- 24 Germany
- 25 c Institute of Computational Biology, Helmholtz Zentrum München, Ingolstädter Landstraße
- 26 1, 85764 Neuherberg, Germany
- d Department of Psychology, LMU Munich, Leopoldstr. 13, 80802 Munich, Germany
- 28 e Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine,
- 29 100 Woodruff Circle, Atlanta GA 30322, USA
- 30 # corresponding author

# 31 Additional information

- 32 wordcount: 6666
- no color for figures in print

# 34 Abstract

35 In a subset of patients with mental disorders, such as depression, low-grade inflammation 36 and altered immune marker concentrations are observed. However, these immune 37 alterations are often assessed by only one data type and small marker panels. Here, we 38 used a transdiagnostic approach and combined data from two cohorts to define subgroups 39 of depression symptoms across the diagnostic spectrum through a large-scale multi-omics 40 clustering approach in 237 individuals. The method incorporated age, body mass index 41 (BMI), 43 plasma immune markers and RNA-seq data from peripheral mononuclear blood 42 cells (PBMCs). Our initial clustering revealed four clusters, including two immune-related 43 depression symptom clusters characterized by elevated BMI, higher depression severity and 44 elevated levels of immune markers such as interleukin-1 receptor antagonist (IL-1RA), C-45 reactive protein (CRP) and C-C motif chemokine 2 (CCL2 or MCP-1). In contrast, the RNA-46 seq data mostly differentiated a cluster with low depression severity, enriched in brain

47 related gene sets. This cluster was also distinguished by electrocardiography data, while 48 structural imaging data revealed differences in ventricle volumes across the clusters. 49 Incorporating predicted cell type proportions into the clustering resulted in three clusters. 50 with one showing elevated immune marker concentrations. The cell type proportion and 51 genes related to cell types were most pronounced in an intermediate depression symptoms 52 cluster, suggesting that RNA-seg and immune markers measure different aspects of immune 53 dysregulation. Lastly, we found a dysregulation of the SERPINF1/VEGF-A pathway that was 54 specific to dendritic cells by integrating immune marker and RNA-seg data. This shows the 55 advantages of combining different data modalities and highlights possible markers for further 56 stratification research of depression symptoms.

57

# 58 Keywords

59 Major depressive disorder; Immunopsychiatry; CRP; IL-1RA; Multi-omics; Transdiagnostic;
60 BMI; Chemokines; RNA-seq

# 61 1. Introduction

Mental disorders significantly impact human health, health care systems, and economies,
accounting for up to 16% of global disability-adjusted life years (Arias, Saxena, and Verguet
2022). Despite this substantial impact, the development of effective and innovative
treatments remains a challenge (O'Donnell et al. 2019). Major depressive disorder (MDD)
exemplifies these challenges, being the foremost psychiatric contributor to global disability
(Vos et al. 2020).

The difficulty in understanding the underlying molecular causes of MDD arises from itsbiological heterogeneity. MDD manifests with a wide range of symptoms and is often

71 comorbid with other mental disorders (Kessler et al. 2017; Kaufman and Charney 2000). 72 which complicates its precise characterization. While the heritability of depression has been 73 known for decades (McGuffin et al. 1996), genome-wide associations studies (GWASs) 74 using minimal phenotyping have only yielded significant insights with extremely large sample 75 sizes (Howard et al. 2019). Adopting a transdiagnostic approach that includes disorders 76 across diagnostic categories and uses biological pathways, revealed associations between 77 GWAS findings from MDD, schizophrenia and bipolar disorder with cytokine and immune 78 pathways (O'Dushlaine et al. 2015).

79

80 Further evidence supports the pivotal role of the immune system in the pathology of MDD. 81 Stress, a risk factor for depression, can lead to increased inflammation (Hammen 2015; 82 Rohleder 2019). Accordingly, a subgroup of roughly 30% of MDD patients shows a 83 proinflammatory profile - often referred to as low-grade inflammation - characterized by 84 elevated levels of C-reactive protein (CRP) (Osimo et al. 2019). Our recent research 85 corroborated this observation of immune-related depression, demonstrating genetic correlation between increased CRP level and depressive symptoms, e.g., tiredness, 86 87 changes in appetite, anhedonia and feelings of inadequacy (Kappelmann et al. 2021). 88 Immune markers such as interleukin (IL)-6, IL-1beta and tumor necrosis factor (TNF) are 89 often measured to evaluate immune dysregulation (Haapakoski et al. 2015) and contain 90 genetic variants relevant for depression (Barnes, Mondelli, and Pariante 2017). Several 91 studies have provided evidence that an inflammatory stimulus can lead to depressed mood, 92 and that the pre-existing inflammatory status can predict the severity (Lasselin et al. 2020; 93 Cho et al. 2019). For an overview on how cytokines and immune cells may mediate 94 depressive symptoms see Miller and Raison 2016.

95

Many studies have employed case-control designs to find differences in immune markers
between individuals with depression and healthy controls (Wittenberg et al. 2020; Sørensen
et al. 2023; Sforzini et al. 2023). At the same time, various studies have established the link

99 between specific depressive symptom profiles and inflammation. Increased inflammation has 100 been observed in patients with dysregulated metabolism (immuno-metabolic depression) 101 and linked to anhedonia (Lamers et al. 2013: Milaneschi et al. 2020: Felger et al. 2016: 102 Lucido et al. 2021). A study by Franklyn et al. 2022 found that inflammation is associated 103 with symptoms like altered eating patterns, appetite and tiredness. Lynall et al. 2020 104 focusing on immune cell counts, identified a subgroup of depressed patients with increased 105 levels of monocytes, CD4+ T cells and neutrophils. This subgroup also demonstrated 106 increased CRP and IL-6 levels, correlating with more severe depressive symptoms. 107

108 The potential of an inflammatory subtype goes beyond symptom profiles, as a study by 109 Cattaneo et al. 2020 identified differences in whole blood gene expression related to 110 inflammation that differentiate patients with treatment-resistant depression from those 111 responding to treatment. Such findings highlight the potential of precisely characterizing 112 immune dysfunction within MDD, aiming to identify patients who might benefit significantly 113 from targeted immunomodulation. In recent years, several randomized control trials 114 evaluated the effectiveness of adding an anti-inflammatory medication to antidepressants. 115 Some of these trials adopted elevated CRP concentration as an inclusion criterion or a 116 measure for secondary analyses. While there is some evidence for beneficial effects (Savitz 117 et al. 2018; Köhler-Forsberg et al. 2019; Nettis et al. 2021), several other studies reported no 118 discernible differences between patients treated with anti-inflammatory medication or those 119 receiving placebos (Husain et al. 2020; Hellmann-Regen et al. 2022), even when stratified 120 by CRP (Baune et al. 2021). Inspired by advancements in cancer research, Miller and 121 Raison 2023 suggest shifting from traditional diagnostic evaluations to focusing on 122 symptoms influenced by inflammation, such as anhedonia, changes in appetite and sleep 123 (Drevets et al. 2022). This shift underpins our use of a transdiagnostic cohort, aiming to 124 transcend diagnostic boundaries and explore common biological underpinnings across 125 psychiatric conditions.

126

127 This push towards a more integrative and holistic understanding aligns with the broader field 128 of psychoneuroimmunology. Traditionally, many studies in this area have relied on single 129 omics approaches (e.g., transcriptomics or protein concentrations of peripheral immune 130 markers). However, with the recent advancements in multi-omics techniques such as 131 clustering or factor analysis methods (Li et al. 2021), there is an opportunity to integrate 132 these individual omics data sets. Together with data from psychological assessments. 133 imaging, and wearable devices (Moshe et al. 2021; Seppälä et al. 2019), we can further 134 elucidate the complex interplay between the immune system and mental disorders by 135 correlating molecular disease pathologies with clinical data (Mengelkoch et al. 2023: Halaris 136 et al. 2019). 137 Building on this integrated approach, we selected a transdiagnostic sample of 237 138 individuals from two different cohorts with broad clinical assessments. Our goal was to 139 comprehensively explore the relationship between the immune system and depression 140 symptoms across the diagnostic spectrum utilizing multi-omics clustering techniques and 141 considering a range of diagnoses of mental disorders. We hypothesized that distinct 142 subgroups, defined by biological indicators of inflammation, would show different clinical and 143 behavioral profiles. Furthermore, we measured an immune marker panel (p=43 markers) 144 and the RNA-sequencing (seq) data (p=12210 genes) from their plasma and peripheral 145 blood mononuclear cells (PBMCs), respectively. Using both the immune markers and RNA-146 seq data, we clustered the participants and characterized the unique clinical profiles of each

#### 147 subgroup (Figure 1).





149 Figure 1: Analysis overview: 237 participants with a DSM-IV (subthreshold) diagnosis according to the Munich-150 Composite International Diagnostic Interview were clustered with a multi-omics clustering. The different layers 151 contained phenotypes (age and BMI, orange), 43 immune markers measured in plasma (green) and RNA-seg 152 from peripheral blood mononuclear cells (PBMCs, blue). The clustering was performed repeatedly as a 153 consensus clustering on subsets of the data to obtain stability metrics for the optimal number of clusters. The 154 stratification into clusters was characterized by several phenotypes. MIDS = mild depression symptoms cluster, 155 HIRDS = high immune-related depression symptoms cluster, LIRDS = low immune-related depression symptoms 156 cluster.

# 157 2. Methods

158 For detailed methods see the Supplementary Methods.

## 159 2.1 Sample selection

- 160 The study sample comprised 246 participants from the Biological Classification of Mental
- 161 Disorders (BeCOME) study (ClinicalTrials.gov: NCT03984084, Bruckl et al. 2020) and 115
- 162 participants from the OPtimized Treatment Identification at the MAx Planck Institute
- 163 (OPTIMA) study (ClinicalTrials.gov: NCT03287362, Kopf-Beck et al. 2020). The Munich-
- 164 Composite International Diagnostic Interview (DIA-X/M-CIDI, Wittchen et al. 1995; Wittchen
- and Pfister 1997) was employed to assess all participants. Out of these with immune marker
- 166 measurement, 237 affected participants (BeCOME=134, OPTIMA=103, Figure S1) met
- 167 either threshold or subthreshold DSM-IV DIA-X/M-CIDI criteria for any substance use,

168 affective or anxiety disorder including post-traumatic stress disorder and obsessive-

- 169 compulsive disorder within the last 12 months. 192 of these participants had a
- 170 (subthreshold) DSM-IV diagnosis of major depression or dysthymia. We also included 36
- 171 mentally healthy participants from the BeCOME study without any DSM-IV IDA-X/M-CIDI
- 172 diagnosis as controls.

## 173 2.2 Ethics approval and informed consent

- 174 The BeCOME and OPTIMA studies were approved by the ethics committee of the Ludwig
- 175 Maximilian University, in Munich, Germany, under the reference numbers 350–14 and 17–
- 176 395, respectively. Written informed consent was obtained from all participants before study
- 177 enrollment.

### 178 2.3 Assessments

### 179 2.3.1 Questionnaire data

- 180 All participants were assessed by the Beck Depression Inventory (BDI) II (Hautzinger, Keller,
- 181 and Kühner 2006) and the Montgomery–Åsberg Depression Rating Scale (MADRS,
- 182 Schmidtke et al. 1988). An overview about the sample characteristics for this subset are
- 183 provided in Table 1, for more details see Table S1.
- 184
- 185 Table 1: Cohort overview with either percent of participants and absolute numbers in brackets or mean and
- 186 standard deviation in brackets. The depression diagnosis was assessed by the Munich-Composite International
- 187 Diagnostic Interview and includes full and subthreshold cases. Psychotropic drugs include antidepressants,
- 188 moodstabilizer, neuroleptics, tranquilizer and herbal psychotropics. BDI = Beck Depression Inventory. Information

189 on other diagnoses of mental disorders are available in Figure S5, on somatic diseases and medication in Table

190 S1. MDD = major depressive disorder

statu	n	age	female	BMI	MDD or	BDI	psychotropic
s					dysthymia		drugs
					diagnosis		
case	237	38.8	58%	25	81% (192)	23.6	43% (103)
		(13.3)	(138)	(5.2)		(13.2)	
contr	36	31.4	61%	23.7	0% (0)	2 (2.9)	0% (0)
ol		(9.4)	(22)	(2.8)			

### 191 2.3.2 Blood collection

192 Blood was collected in the morning under fasted conditions, peripheral blood mononuclear

193 cells (PBMCs) were extracted and stored at the biobank.

### 194 2.3.3 Immune marker measurements

195 We used the V-PLEX Human Biomarker 54-Plex Kit (Meso Scale Diagnostics (MSD),

196 Rockville, USA, Cat. No. K15248G-2) to measure immune markers in plasma. In addition,

197 enzyme-linked immunosorbent assay (ELISA) was used to measure the following markers:

198 high-sensitivity C-reactive protein (hsCRP, Tecan Group Ltd., Männedorf, Switzerland, Cat.

199 No. EU59151), cortisol (Tecan Group Ltd., Männedorf, Switzerland, Cat No. RE52061),

- 200 interleukin (IL)-6 (Thermo Fisher Scientific, Waltham, USA, Cat. No. BMS213HS), IL-6
- soluble receptor (sIL-6R, Thermo Fisher Scientific, Waltham, USA, Cat. No. BMS214) and
- 202 IL-13 (Thermo Fisher Scientific, Waltham, USA, Cat. No. BMS231-3). All assays were
- 203 performed according to the manufacturer's instructions. Immune markers with high
- sensitivity alternatives or with more than 16% missing values, along with participants

showing hsCRP levels suggestive of acute infection, were excluded. This resulted in 43

- 206 markers and 273 participants remaining for analysis (Table S2 and Figure S1).
- 207 2.3.4 RNA extraction and sequencing
- 208 The RNA was extracted with the chemagic 360 instrument (PerkinElmer, Waltham, USA),
- 209 rRNA depleted, libraries prepared with the Lexogen CORALL total RNA-Seq Library Prep Kit
- 210 with UDIs 12 nt Sets A1-A4 (Cat. No. 117.96, 132.96, 133.96, 134.96) and sequenced on an
- 211 NovaSeq 6000 (Illumina, San Diego, USA) yielding an average of 30.6 million paired reads
- 212 per library.
- 213 2.3.5 Structural magnetic resonance imaging (MRI) data assessment
- 214 151 affected participants (BeCOME=117 and OPTIMA=34) and 29 healthy controls had high
- 215 resolution T1-weighted images with the identical sequence in both original studies (Sagittal
- 216 FSPGR 3D BRAVO, TE 2.3 ms, TR 6.2 ms, TI 450 ms, FA 12°, FOV 25.6 × 25.6 × 20.0
- 217 cm3, matrix 256 × 256, voxel size 1 × 1 × 1 mm3) available.
- 218 2.3.6 Electrocardiography data assessment
- 149 affected participants (BeCOME=108 and OPTIMA=41) and 32 healthy controls had an
  electrocardiography (ECG) recording that spanned 24h including a sleeping period with the
  portable ECG-device Faros 180 (Mega Electronics Ltd, Kuopio, Finland) at a sampling
  frequency of 500 Hz available.
- 223 2.4 Data analysis
- 224 2.4.1 Immune marker analysis

The immune markers were quantile-normalized and corrected for the biobank storage
position. For each immune marker, a linear model was fitted in R version 4.0.2 (R Core

Team 2023) to regress out the batch variable. The residuals from this regression were thenused for downstream analysis.

- 229 2.4.2 RNA-seq analysis
- 230 The reads were aligned to GRCh38.p12 (Ensembl version 97, Martin et al. 2023) with STAR

version 2.7.7a (Dobin et al. 2013) and counted with featureCounts version 1.6.4 (Liao,

232 Smyth, and Shi 2014).

233 Quality control and exclusion of genes with few counts or high GC content influence left 229

affected participants, 33 controls and 12210 genes (Figure S1). The data was sequentially

corrected for the GC content and a preparation batch variable with ComBat\_seq from the

sva package version 3.38.0 (Leek et al. 2021) and normalized with vst from DESeq2 version

237 1.30.1 (Love et al. 2021).

### 238 2.4.3 Cell type deconvolution

The filtered RNA-seq count data, which was not batch-corrected, was converted to TPM and deconvoluted using the granulator package version 1.6.0 (Pfister, Kuettel, and Ferrero 2023) in R version 4.2.0 (R Core Team 2023). All cell types with a standard variation of less than 0.5 were excluded, resulting in 14 cell types.

243 2.4.4 Multi-omics clustering and statistical analysis of cluster differences

Each variable of the normalized and batch corrected immune marker and RNA-seq data as

245 well as age and BMI was standardized, the distance between the participants calculated and

the clustering method SUMO version 0.3.0 (Sienkiewicz et al. 2022) was applied repeatedly

on a subsample to calculate stability metrics for selecting the number of clusters.

If not otherwise stated, we used R version 4.0.2 (R Core Team 2023) and determined the

variable importance based on the F-value from ANOVA tests. A higher variable importance

250 indicates a more distinct separation between the clusters. For continuous variables not used

- in the clustering, we applied the Tukey Honest Significant Differences (TukeyHSD) test and
- 252 reported adjusted p-values, for categorical variables the Fisher's exact test.
- 253 We did not report p-values for group differences for variables that were used in the clustering
- as differences were anticipated (Kriegeskorte et al. 2009).

### 255 2.4.5 Gene set analysis

- 256 For each participant, a score was calculated for every biological process and molecular
- 257 function GO term gene set using GSVA version 1.36.3. (Hänzelmann, Castelo, and Guinney
- 258 2013) based on the batch-corrected and normalized RNA-seq data. The distribution of these
- 259 gene set scores across clusters was tested using an ANOVA and F-values reported as
- 260 variable importance.

### 261 2.4.6 Prediction of responder status

The baseline values from gene expression data with accession number GSE45468 were mapped to ENSEMBL IDs. 8431 genes overlapped with our data and were used in a lasso model using glmnet version 4.1-8 (Friedman et al. 2023), the p-value was empirically

calculated based on random genes.

### 266 2.4.7 Imaging analysis

267 Morphological differences were investigated at the global, regional (FreeSurfer) and voxel

268 level. FreeSurfer v7.1.1 (Fischl 2012) based phenotypes were restricted to those with strong

- 269 meta-analytical evidence for an effect in MDD (Schmaal et al. 2016; 2017). Analysis of
- 270 covariance (ANCOVA) was applied to the clusters covarying for intracranial volume, age and
- sex, and cluster effects were FDR corrected at 5%.

### 272 2.4.8 Electrocardiography analysis

- 273 Raw data was preprocessed using the PhysioNet Cardiovascular Signal Toolbox (Vest et al.
- 274 2018) in Matlab version 2020b (The MathWorks Inc. 2020). Time domain metrics were
- 275 calculated for every minute using a sliding window of 5 minutes.
- 276 2.4.9 Single-cell RNA-seq data analysis
- 277 Single cell PBMC RNA-seq data from 14 individuals with depression and other mental
- disorders with accession number GSE185714 was processed with scanpy version 1.9.3
- (Wolf, Angerer, and Theis 2018) according to Schmid et al. 2021 and their cell type labelsused.
- 281 3. Results
- 3.1 Multi-omics clustering with age, BMI, immune markers and
- 283 RNA-seq data identified 4 clusters with different depression
- 284 severity and inflammation status

285 To discover subgroups with immune-related depression symptoms, we assessed a 286 comprehensive immune marker panel (p = 43 markers) along with matched RNA-seq data (p 287 = 12210 genes) in 237 participants (Figure S1) diagnosed with MDD or another stress-288 related mental disorder within the last 12 months. The mean age of the affected participants 289 was 39 years and the mean BMI 25 (see Table 1 for sample characteristics). Besides the 290 biological data, the participants underwent phenotypic assessment. Our approach involved 291 clustering the participants based on multiple biological datasets and subsequently 292 characterizing these subgroups using psychometric data.

293

294 For multi-omics clustering, we employed SUMO (Sienkiewicz et al. 2022), a non-negative 295 matrix factorization based clustering algorithm, that provides cluster stability metrics via 296 consensus clustering. This method organizes variables into lavers and computes the 297 distance between the participants within each layer, which subsequently informs the 298 clustering process. For our study, age and BMI were combined as one layer while the 299 immune markers and RNA-seg data were each defined as separate layers. According to the 300 built-in stability metrics (Figure S2A-B), this approach yielded a four cluster solution. These 301 clusters included 121, 58, 39 and 19 participants, respectively (Table S3). In light of the 302 findings described below, we termed cluster 1 *mild depression symptoms* cluster (MIDS). 303 cluster 2 high immune-related depression symptoms cluster (HIRDS) 1, cluster 3 low 304 immune-related depression symptoms cluster (LIRDS) and cluster 4 HIRDS2. Each of the 305 identified clusters showed a different pattern of immune markers and contained participants 306 from both the BeCOME and OPTIMA cohorts, which differ in the in- and outpatient ratio, 307 psychopharmacological drug use and sex distribution (see Figures 2A and S3). The 308 significantly different distribution of the cohorts across the clusters (Fisher's exact test, p = 309 0.000003) was driven by the MIDS cluster; between the LIRDS and HIRDS clusters there 310 was no different distribution (Fisher's exact test, p = 0.507320).



312 Figure 2: Initial clustering with age, BMI, immune markers and RNA-seq data. (A) Heatmap of immune markers 313 where the columns are participants while the cohort and cluster are noted at the top. The color denotes the 314 normalized concentration with green values missing. (B) Barplot displaying the variable importance of the top 40 315 variables that most differentiate the clusters, calculated using the F-value from an ANOVA model with the 316 clusters as independent variables. These variable importance values should not be interpreted as p-values. 317 because the variables were used in the clustering themselves and therefore inflate the p-values. Violin plots 318 depicting the distribution of (C) age and (D) BMI across the clusters. N = 36 healthy controls not used in the 319 clustering, MIDS = mild depression symptoms cluster, HIRDS = high immune-related depression symptoms

320 cluster, LIRDS = low immune-related depression symptoms cluster, cohort 1 = OPTIMA, cohort 2 = BeCOME.

### 321 3.1.1 BMI, age, IL-1RA, NRCAM and CRP identified as top

### 322 differentiating variables

323 In order to understand which variables drive the clustering, we calculated the variable 324 importance (VI) based on an ANOVA model (Table S4). Figure 2B illustrates that BMI (VI = 325 139.8) and age (VI = 114.8) were most important for the clustering, followed by interleukin 1 326 receptor antagonist (IL-1RA, VI = 35.7). Other important immune markers included high-327 sensitivity C-reactive protein (CRP, VI = 21), placental growth factor (PIGF, VI = 17.1), C-C 328 motif chemokine 2 (CCL2 or MCP-1, VI = 17), tumor necrosis factor (TNF, VI = 15.4), CCL4 329 (MIP-1beta, VI = 14.4) and CCL13 (MCP-4, VI = 13.1). Among the genes, neuronal cell adhesion molecule (NRCAM, VI = 21.8), nucleosome assembly protein 1 like 2 (NAP1L2, VI 330 331 = 21), fibulin 2 (FBLN2, VI = 18.7), 2-phosphoxylose phosphatase 1 (PXYLP1, VI = 17.4), 332 SH3 domain containing ring finger 3 (SH3RF3, VI = 16.6), ectodysplasin A (EDA, VI = 15.8) 333 and XK related X-linked (XKRX, VI = 15.7) were the most important. The genetic location of 334 these genes are noted in Table S5, compared to the overall chromosomal distribution the top 335 100 genes show an enrichment in chromosome 7 (Figure S4). The importance of age and 336 BMI in the clustering process was reflected in their distribution across clusters, as shown in 337 Figure 2C-D. Age demonstrated an increase from MIDS through to HIRDS2. Notably, 338 HIRDS2 and especially HIRDS1 showed elevated BMIs (mean BMI of 27 and 32, 339 respectively) compared to the other clusters.

340

341	Next, we aimed to provide insights into the distribution of age, BMI, and CRP concentration
342	across the clusters due to their importance in the clustering and the established role of CRP
343	as a standard marker for inflammation. Notably, in all clusters except HIRDS2, a positive
344	correlation was observed between CRP concentration and BMI. Specifically, for the MIDS
345	cluster the Pearson correlation was 0.13 (t-test, p = 0.155); for HIRDS1, it was 0.40 (t-test, p
346	= 0.002); for LIRDS, it was 0.39 (t-test, $p = 0.015$ ); and for HIRDS2 it was -0.61 (t-test, $p =$
347	0.006), as illustrated in Figure 3A. It also shows that the HIRDS clusters predominantly
348	contained individuals with elevated CRP concentration and elevated BMI. As illustrated in
349	Figure 3B, no significant correlation between age and CRP was discernible within the
350	clusters, with Pearson correlations ranging between -0.16 and 0.01. Interestingly, the LIRDS
351	cluster contained individuals with a restricted age range. Further examination revealed no
352	strong correlation between age and BMI except for HIRDS2, with Pearson correlations
353	ranging from 0.09 to 0.40, which were not significant (Figure 3C). Notably, while the
354	individuals with a high BMI in HIRDS1 spanned a wide age range, HIRDS2 consisted mostly
355	of individuals aged 50 or above.



357 Figure 3: Distribution of biological and phenotype data across the clusters in the initial clustering with age, BMI. 358 immune markers and RNA-seq data. (A) - (C) Scatterplots illustrate the associations between C-reactive protein 359 (CRP), BMI and age across the four clusters, as determined by locally estimated scatterplot smoothing (LOESS). 360 (D) Violin plots showing the distribution of Beck Depression Inventory (BDI)-II across the clusters. Significant 361 differences (p < 0.05) were observed when comparing HIRDS1, LIRDS and HIRDS2 to the MIDS cluster. (E) 362 Violin plots illustrating the Standard Deviation of normal-to-normal intervals (SDNN), a measure for heart rate 363 variability, for 149 participants. The significant differences (p < 0.05) were observed between HIRDS1, LIRDS 364 and HIRDS2 compared to the MIDS cluster. (F) Violin plots illustrating the the cluster-specific effect (global 365 intercept + cluster-specific effect + residuals) of the lateral ventricle volume from a model including age, sex and 366 intracranial volume (ICV) derived from structural magnetic resonance imaging for 151 participants. A significant 367 difference (p < 0.05) was observed between the clusters. Because of the modeling approach, no value for the 368 controls can be shown. MIDS = mild depression symptoms cluster, HIRDS = high immune-related depression 369 symptoms cluster, LIRDS = low immune-related depression symptoms cluster.

# 370 3.1.2 Clinical phenotypes, imaging features and heart rate data identified

### 371 clusters with elevated depression severity

372 Next, we explored how the clusters, which were defined solely based on biological data 373 (including immune markers, RNA-seg data, BMI, and age) without considering depression 374 severity or symptoms, corresponded to these measures of depression post-clustering. 375 Interestingly, the LIRDS and HIRDS clusters exhibited greater depression severity, as 376 measured by the Beck Depression Inventory-II (BDI), than the MIDS cluster (Tukey HSD test 377 with adjusted p values, p = 0.028961, p = 0.000003 and p = 0.001172, respectively). This 378 severity was especially pronounced in the HIRDS clusters (Figure 3D). A similar result was 379 observed using the Montgomery-Åsberg Depression Rating Scale (MADRS) with p-values 380 of 0.009829, 0.000466 and 0.003718 (Tukey HSD test with adjusted p values) for the LIRDS and HIRDS clusters, respectively. The proportion of individuals with either no depression or 381 382 dysthymia diagnosis was not equal across the clusters (Fisher's exact test, p = 0.000500, 383 Figure S5), the MIDS cluster had the highest proportion of participants without such a 384 diagnosis and also the lowest depression severity. While no single item of the BDI 385 differentiated the cluster, there was a trend towards increased sleeping and appetite in the 386 HIRDS clusters as indicated by the BDI (Figure S6A-B).

387

388 To further assess if the identified symptom differences were mirrored in other biological data, 389 we analyzed heart rate data collected from portable ECG devices (n = 149) and structural 390 imaging-derived features (n = 151) in a subset of the participants for whom these data were 391 available. While there were no discernable differences in the median minimum or maximum 392 normal-to-normal intervals between heartbeats between the clusters (Figure S6C), the heart 393 rate variability metrics - for short-term (RMSSD) and long-term (SDNN) - were lower in the 394 LIRDS and HIRDS clusters in comparison to the MIDS cluster (Figure 3E). The p-values for 395 these differences ranged from 0.000039 to 0.005874 for RMSSD and from 0.000112 to 396 0.005446 for SDNN (Tukey HSD test with adjusted p values). The clusters showed a trend of different total brain volume (TBV) (F = 2.406, p = 0.070), with LIRDS showing higher TBV
compared to the MIDS and HIRDS clusters; a similar pattern was seen for gray matter (GM)
and white matter (WM) (Table S6). Regional analyses of 17 MDD-related phenotypes
revealed robust effects on the lateral ventricle volume (F = 5.398, FDR adjusted p = 0.029,
with the lowest volume in LIRDS, see Figure 3F), and nominal significant effects for the right
rostral anterior cingulate and the bilateral hippocampus (Table S7). Voxel-based
morphometry revealed no cluster main effects.

404 3.1.3 Immune markers and genes revealed differences in immune

405 system and brain related pathways between clusters

406 We wanted to understand how the immune markers and RNA-seq data each contributed to

407 defining the clusters, and if these different data types contained distinct information.

408 Interestingly, except for CCL13, all the top important immune markers were elevated in the

409 HIRDS clusters (Figure 4A). These clusters not only showed increased BMI but also the

410 highest BDI. This distinctive pattern was reflected in CCL13's low correlation with key

411 markers such as IL-1RA and CRP (Figure 4D). While still discriminating the HIRDS clusters

412 from the others, PIGF also had a similar low correlation with the top markers IL-1RA and

413 CRP (Figure 4D). All top immune markers showed a positive correlation with BMI (Figure

414 S7).

415

In contrast, the most discriminating genes mainly differentiated the MIDS cluster, defined by a low depression severity, from the other clusters (Figure 4B). Accordingly, the correlations between the genes were stronger than those among immune markers, with the exception of the correlation between *EDA* and *NAP1L2*. On average, the absolute correlation between the top genes was 0.36, while it was 0.27 between the top immune markers (Figure 4E). To link the findings to clinical data, we investigated if the top discriminating genes could predict the responder status in patients with depression to treatment with an antibody against TNF

- 423 in an external data set (Mehta et al. 2013). Based on the area under the curve (AUC), the
- 424 top 10 and top 20 genes did not perform better than random genes (permutation test, p =
- 425 0.139 and p = 0.159). The most important gene for the 20-gene-model was vesicle
- 426 associated membrane protein 1 (VAMP1), which was also included in the 10-gene prediction
- 427 model, although it was not statistically significant.





Figure 4: Immune marker and RNA-seq data contains complementary information in the initial clustering with age, BMI, immune markers and RNA-seq data. (A) Violin plots showing the distribution of the seven most differentiating immune markers across the clusters. (B) Violin plots showing the distribution of the seven most differentiating genes across the clusters. (C) Heatmap of the 20 most differentiating GO gene sets ordered by their variable importance that are enriched in the clusters. These gene sets were identified through Gene Set

Variation Analysis (GSVA). (D) Heatmap showing the Pearson correlation between the top immune markers. (E)
Heatmap showing the Pearson correlation between the top genes. MIDS = mild depression symptoms cluster,
HIRDS = high immune-related depression symptoms cluster, LIRDS = low immune-related depression symptoms
cluster.

438 To understand the underlying molecular mechanisms, we analyzed not only individual genes 439 but also their coordinated expression patterns, examining these genes in the context of 440 pathways. We applied gene set enrichment analysis using GSVA (Hänzelmann, Castelo, 441 and Guinney 2013) to calculate gene set scores for every participant and compared the 442 distribution across clusters (Table S8). As depicted in Figure 4C, the gene sets that stood 443 out prominently were enriched in the LIRDS and HIRDS clusters. Interestingly, these gene 444 sets included those related to the brain (e.g., anterograde axonal transport, VI = 17.3, 38 445 genes), immune system (regulation of macrophage activation, VI = 12.5, 32 genes), stress 446 response (response to mineralocorticoid, VI = 12.4, 15 genes) and (ion) transport (e.g., 447 regulation of calcium ion transmembrane transporter activity, VI = 13.1, 44 genes).

### 448 3.2 Re-evaluating the initial clustering adjusted for age, BMI

## and sex showed no phenotypic differences

450 Considering the strong impact of BMI and age on the clustering outcomes, we re-evaluated 451 the clustering by first adjusting the biological data for age, BMI and sex using a linear model, 452 and then applying the clustering algorithm. After adjusting the data, we obtained a three 453 cluster solution (Figure S2C-D), which differed from the four clusters identified in the initial 454 analysis (Figure S8A). Notably, in the re-evaluated clustering, the variable importance of the 455 immune markers was diminished relative to the RNA-seq data (Table S9). Among the 456 immune makers, IL-27 stood out with the highest immune marker variable importance of 7.4. 457 Contrastingly, the gene CKLF like MARVEL transmembrane domain containing 6 (CMTM6) 458 showed a much higher variable importance of 77.4. Moreover, the primary discriminative 459 immune markers or genes in this analysis were different from those in our initial clustering

460 (Figure S8B). Compared to the genes, the distribution of the immune markers across the
461 clusters was more uniform (Figure S8C-D). There were no significant differences of age,
462 BMI, BDI or MADRS sum scores between the clusters (Figure S8E-G).

## <sup>463</sup> 3.3 Re-evaluating the initial clustering including cell types

## <sup>464</sup> identified three clusters predominantly driven by RNA-seq data

465 Given the previous findings that highlight the significance of blood cell type composition in 466 discerning depression subgroups (Lynall et al. 2020), we integrated cell types into a new 467 clustering model aligning them in one laver with age and BMI. We did not have cell counts 468 available but deconvoluted cell type proportions from the RNA-seq data. The predominant 469 cell types in our sample were "T cells CD4 memory resting" (median fraction of 0.41) and 470 "Macrophages M1" (median fraction of 0.15, see Figure 5A). The new clustering led to a 471 three cluster solution (Figure S2E-F). Cluster 1 contained mostly (85.7%) individuals that 472 were assigned to the MIDS cluster in the initial clustering without the inclusion of cell types. 473 Cluster 3 contained predominantly individuals from the clusters with high BMI and high BDI 474 (HIRDS clusters, 69.2%) as determined from the initial clustering. Cluster 2 presented a mix, 475 drawing from different groups of the initial clustering: 54.2% from MIDS, 17.7% from 476 HIRDS1, 24% from LIRDS and 4.2% from HIRDS2 (Figure 5B). Accordingly, we termed the 477 clusters reMIDS, intermediate depression symptoms cluster (reIDS) and reHIRDS.



478

479 Figure 5: Re-clustering with age, BMI, cell types, immune markers and RNA-seq data. (A) Stacked barplot 480 illustrating the proportion of various cell types predicted from the RNA-seq data for all participants. (B) Mapping of 481 the participants from the initial clustering to the re-evaluated clustering that additionally contains cell type 482 proportions. (C) Barplot showing the variable importance of the top 30 variables that most differentiate the 483 clusters, along with the 10 most differentiating biological variables and immune markers. (D) Violin plots 484 illustrating the predicted cell type proportions across the clusters. (E) Heatmap of the 20 most differentiating GO 485 gene sets, ordered by their variable importance, that are enriched in the clusters. These gene sets were identified 486 through Gene Set Variation Analysis (GSVA). reMIDS = re mild depression symptoms cluster, reIDS = re 487 intermediate depression symptoms cluster, reHIRDS = re high immune-related depression symptoms cluster, NK 488 = natural killer cells.

#### 489 3.3.1 T cell proportions and RNA-seq data were important for the

### 490 clustering

491 The distribution of age and BMI demonstrated an increasing trend across the clusters, 492 especially BMI was markedly increased in the reHIRDS cluster, with 29.1 compared to 22 for 493 the reMIDS cluster and 23.7 for the reIDS cluster (Figure S9A-B). In line with the pattern 494 seen in the initial clustering, the reHIRDS cluster showed significantly elevated BDI 495 compared to the other clusters (Tukey HSD test with adjusted p values, p = 0.000126 for 496 cluster 1 and p = 0.008659 for cluster 2, Figure S9C), and the MADRS in the reHIRDS 497 cluster was elevated compared to the reMIDS cluster (Tukey HSD test with adjusted p 498 values, p = 0.013896) as well.

499

500 In reassessing the variables contributing to the clustering, we observed a shift from our initial 501 findings. While age and BMI were the most important variables in the initial clustering, their 502 impact reduced in the re-evaluation. BMI still remained the second most important biological 503 variable (VI = 53.5, Figure 5C and Table S10), ranking 77th overall, but age (VI = 19.5) 504 dropped to the 2037th position. The top 7 immune markers were the same as in the initial 505 clustering except CXCL10 (IP-10, VI = 29.3) replacing CRP (VI = 21.3). However, in the 506 reclustering the immune markers ranked 240th to 1484th in the variable importance, 507 whereas in the initial clustering 3rd to 24th. The cell type "T cells CD4 memory resting" 508 emerged as the most important biological variable (VI = 79.1), also being the most prevalent 509 cell type in our sample (Figure 5A). Other notable cell types included "Dendritic cells 510 activated" (VI = 31.7) and "Monocytes" (VI = 26.6). In the reMIDS cluster, "T cells CD4 511 memory resting" showed an increased mean proportion of 0.48 compared to 0.36 and 0.40 512 in the other clusters, while the "Dendritic cells activated" and "Monocytes" were decreased in 513 the reMIDS cluster (Figure 5D). Furthermore, Figure 5C shows that genes were the essential 514 variables to discriminate between the clusters (see Supplementary Results for more details).

515

### 516 3.3.2 Pathway analysis identified immune system involvement

517 Next, we performed gene set enrichment analysis to analyze the biological pathways that 518 differed between the cluster. As highlighted in Figure 5E, the most discriminative gene sets 519 were downregulated in the reMIDS cluster, upregulated in the reIDS cluster and moderately 520 upregulated in the reHIRDS cluster. Closer examination revealed that these gene sets were 521 enriched for terms related to the immune system (response to molecule of bacterial origin, VI 522 = 119, 186 genes), secretion (regulation of secretion, VI = 118.1, 297 genes), 523 transmembrane transport (regulation of transmembrane transport, VI = 108, 237 genes) and 524 neurons (positive regulation of neuron death, VI = 103.7, 58 genes) among others (Table 525 S11).

526 3.4 Integration of protein and RNA-seq data with single cell

### 527 expression showed cell type specific regulation of inflammation

528 To further elucidate the characteristics of the high depression severity clusters from our 529 initial clustering model delineated in Figure 2, we analyzed the genes and immune markers 530 that differentiated the LIRDS and HIRDS clusters. Two prominent variables emerged: the 531 gene serpin family F member 1 (SERPINF1, VI = 9.1) and the protein vascular endothelial 532 growth factor A (VEGF-A, VI = 10.1). As represented in Figure 6A and 6B, SERPINF1 533 expression was elevated in the MIDS and LIRDS clusters, coinciding with low VEGF-A 534 protein concentrations. In contrast, the HIRDS clusters displayed an opposite pattern. 535 Interestingly, we did not find differences in the gene expression of VEGFA between the 536 clusters (Figure 6C) and in general low correlation between RNA-seg and corresponding 537 protein level (see Supplementary Results and Figure S10 for more details).

538

The importance of different cell types was underlined by single cell gene expression
analysis. PBMC RNA-seq data from 14 individuals with depression and other mental

- 541 disorders indicated a predominant SERPINF1 expression in dendritic cells (Figure 6D and
- 542 6F), while VEGFA was mainly expressed in monocytes (Figure 6E-F), showing the
- 543 importance of cell types even when not included directly in the clustering.



545 Figure 6: Cell-type specific dysregulation in the initial clustering with age, BMI, immune markers and RNA-seq 546 data. Violin plots displaying: (A) the gene expression of SERPINF1 across the clusters, (B) normalized protein 547 concentration of VEGF-A across the clusters, and (C) gene expression of VEGFA across the clusters. (D) - (F) 548 Single-cell RNA-seq data of peripheral blood mononuclear cells (PBMCs) from 14 patients with depression and 549 other mental disorders visualized using UMAP plots. (D) Demonstrates the gene expression of SERPINF1. (E) 550 Shows the gene expression of VEGFA. (F) Illustrates the cell types identified within the PBMCs. NK = natural 551 killer cells, MIDS = mild depression symptoms cluster, HIRDS = high immune-related depression symptoms 552 cluster, LIRDS = low immune-related depression symptoms cluster.

# 553 4. Discussion

554 In this study, we analyzed a transdiagnostic sample of individuals with stress-related mental disorders from two cohorts to identify patterns of depression symptoms in relation to immune 555 556 alterations, thereby broadening the understanding of immune-related subgroups in 557 depression. Traditionally, such subgroups have been defined by specific immune markers 558 such as CRP or TNF, known to be increased in some depressed patients (Haapakoski et al. 559 2015; Osimo et al. 2020), especially those resistant to antidepressant treatment 560 (Chamberlain et al. 2019; Yang et al. 2019; Strawbridge et al. 2015). Our large-scale multi-561 omics analysis, integrating gene expression data of 12210 genes with immune marker 562 profiling of 43 makers including CRP, suggests a more complex immune involvement in depression symptoms than indicated by CRP alone. Our approach uncovered four distinct 563 564 clusters dissecting depression symptoms across the diagnostic spectrum: two high immune-565 related-depression symptoms (HIRDS) clusters with increased immune markers, BMI, and 566 depression severity; a *mild depression symptoms* (MIDS) cluster, predominantly younger 567 participants with lower depression severity and minimal immune marker elevation; and a low 568 *immune-related-depression symptoms* (LIRDS) cluster with elevated depression severity but 569 without increased immune markers. This nuanced classification offers deeper insights into 570 the interplay between immune function and depression symptoms.

571

572 Incorporating a multi-omics integration clustering approach has clearly demonstrated its 573 value, providing unique insights through the combination of phenotypic data, immune 574 markers and RNA-seq data. This was especially evident in identifying HIRDS clusters with 575 elevated immune markers such as CRP, TNF, IL-1RA, PIGF, CCL2, CCL4, and CCL13. 576 Measuring IL-1 beta posed a challenge due to its low concentration, even with high-577 sensitivity assays, highlighting the difficulties in detecting certain cytokines. Interestingly, IL-578 1RA, typically anti-inflammatory, is produced under the same inflammatory conditions as the 579 proinflammatory IL-1 beta, linking it to an increased risk of developing depressive symptoms 580 in elderly (Osimo et al. 2020; Milaneschi et al. 2009). Consistent with this, we found 581 heightened IL-1RA levels in our HIRDS clusters, which also exhibit altered appetite patterns, 582 aligning with findings from Simmons et al. 2020. While specific BDI items like increased 583 appetite and hypersomnia showed only a trend, a clear elevation in overall depression 584 severity and BMI was observed. These patterns support the concept of immuno-metabolic 585 depression, where heightened inflammation correlates with disrupted energy balance. 586 manifesting as obesity and fatigue (Lamers et al. 2020; Milaneschi et al. 2020; Simmons et 587 al. 2020).

588 Our research sheds light on the role of less-studied chemokines in depression. Elevated 589 CCL2 in blood, CSF, and in post-mortem brain tissues of depressed patients (Young, Bruno, 590 and Pomara 2014; Eyre et al. 2016; Sørensen et al. 2023; Torres-Platas et al. 2014), 591 alongside mixed data for CCL4 (Camacho-Arroyo et al. 2021; Sørensen et al. 2023; 592 Leighton et al. 2018) and limited research on CCL13, with only one study that found lower 593 levels in suicide attempters (Janelidze et al. 2013), indicate their intricate roles in this 594 symptom spectrum. Additionally, it highlighted PIGF, part of the vascular endothelial growth 595 factor family (De Falco 2012), implicated in angiogenesis, the immune response, and 596 obesity-related processes (Oura et al. 2003; Lijnen et al. 2006), which was previously found 597 to have lower levels in depressed patients (Yue et al. 2016). By employing a multi-panel approach to simultaneously measure a wide array of immune markers, we elucidated the 598 599 complex roles of chemokines and established markers in depression symptom spectrum. 600 This strategy not only identifies specific immune markers associated with depression 601 symptoms but also advances our understanding of the disorder's immunological aspects, 602 suggesting a promising direction for future research.

603

The immune markers were crucial for differentiating between the HIRDS clusters and others, while key genes and the gene set analysis were instrumental in separating between clusters of varying depression severity. The panel of important genes includes genes that are associated with neurodevelopmental disorders (*NRCAM*, Kurolap et al. 2022), neuronal

608 development (NAP1L2, Attia et al. 2007) or that were downregulated in post mortem choroid 609 plexus from patients with MDD (FBLN2, Turner et al. 2014). This underlines that depression 610 not only affects the brain but other tissues as well and demonstrates our approach's 611 effectiveness at identifying genes differentiating depression severity. Our gene set analysis 612 further supports this, revealing a prevalence of pathways related to neurons and axonal 613 transport in the high depression severity clusters. While immune system pathways were 614 enriched in the genes differentiating the clusters, the immune marker data primarily defined 615 the immune-related depression symptom clusters, underscoring the value of this integrative 616 approach.

617

618 The significance of BMI and age in relation to depression symptoms in our analysis added to 619 the ongoing debate about whether BMI adjustments in immune marker analyses clarify or 620 confound the relationship with depression (Horn et al. 2018; Moriarity, Mengelkoch, and 621 Slavich 2023). Several studies suggest that CRP's association with depression is more 622 pronounced without BMI-adjustments (Horn et al. 2018; Chae et al. 2022; Figueroa-Hall et 623 al. 2022). Recently, a simulation study demonstrated that including BMI as a covariate can 624 lead to reduced precision in estimating the relationship of inflammation on depression 625 (Moriarity, Mengelkoch, and Slavich 2023). Consistently, our findings revealed no significant 626 differences in depression severity or inflammation status when adjusting for BMI, sex and 627 age, underscoring the complex interplay among these factors and emphasizing BMI's role as 628 an integral component of the depression phenotype.

629

Our analysis extended beyond clinical depression severity to heart rate variability and
neuroimaging, differentiating the clusters. While not corrected for covariates, heart rate
variability (SDNN) was lower in the LIRDS and HIRDS clusters and could discriminate them
from the MIDS cluster, aligning with previous findings that link reduced heart rate variability
to current and former depression, as well as dysphoria (Hartmann et al. 2019; Koch et al.
2019; Dell'Acqua et al. 2020), which suggests broader physiological implications of

636 depression. Structural neuroimaging revealed a trend of relatively higher total brain volume 637 in the LIRDS cluster compared with the HIRDS and MIDS clusters, with similar effects for 638 GM and WM analyzed separately. Regional analyses confirmed inverse changes of 639 cerebrospinal fluid (CSF), specifically of the lateral ventricle volume. In the presence of acute 640 depressive symptoms, it seems that the LIRDS constellation might protect from CSF 641 including ventricular enlargement. Larger ventricles have been observed in MDD with early 642 disease onset before 21 years of age (Schmaal et al. 2016) and in bipolar disease (Hibar et 643 al. 2016) which could suggest that stronger immune activation might take influence on 644 subclinical or masked bipolar traits. Regional effects as detected for the bilateral hippocampi 645 and the right rostral anterior cingulate cortex, were heterogeneous between the two HIRDS 646 clusters. While these structures were reported before in immune based stratifications (Savitz 647 et al. 2013) and are plausibly involved in stress response regulation (Herman et al. 2016), 648 larger samples are needed to fully map the anatomical characteristics of immune-related 649 depression.

650

651 Our analysis supports the hypothesis that depression is associated with alterations in cell 652 type composition and immune marker levels (Lynall et al. 2020; Foley et al. 2022). 653 Integrating cell type proportions refined our initial clusters, revealing three re-clusters with 654 varying depression severity and aligning well with the initial findings. This highlights the 655 robustness of our subgroups. The reHIRDS cluster, marked by elevated BMI and immune 656 markers, showed an intermediate alteration in T cells CD4 memory resting proportion 657 deviating from Foley et al. 2022 who reported no significant CD4+ T cells proportion 658 changes in depression. Conversely, our reHIRDS and intermediate depression symptoms 659 (reIDS) clusters reflected their findings of decreased lymphocyte percentage in depression. 660 In contrast to the results from Lynall et al. 2020 who observed elevated immune markers and 661 absolute immune cell counts in their immune-related depression cluster, our reHIRDS cluster 662 did not exhibit the strongest cell type phenotype. This discrepancy could stem from 663 methodological differences, such as direct cell counts versus deconvolution. This suggests a

664 complex interplay between immune markers and PBMC composition in depression. Possible 665 sources of immune markers like neutrophils (Tecchio, Micheletti, and Cassatella 2014) and 666 adipose tissue (Fain 2006; Shelton et al. 2015; Shelton and Miller 2011) highlight the 667 importance of obesity in immune-related depression. Our findings emphasize the need for 668 further research into the associations of immune cell composition and immune markers in 669 this context.

670

671 The advantages of a multi-omics integration were further demonstrated by revealing cell type 672 specific inflammation of immune-related depression symptom clusters. VEGF-A was 673 elevated in the HIRDS clusters, contrasting the SERPINF1 expression, which showed the 674 opposite pattern. This aligns with its gene product, pigment epithelium-derived factor 675 (PEDF), known to inhibit VEGF-A (Dawson et al. 1999). Of note, PEDF is neurotrophic 676 (Tombran-Tink and Barnstable 2003) and was shown to ameliorate depression-like 677 symptoms in mice (Tian et al. 2020) and was increased in depression patients after 678 electroconvulsive treatment (Ryan et al. 2017). This suggests a link of the dysregulated 679 immune pathway in the HIRDS clusters and the observed elevated depression severity. 680 Furthermore, our single cell data revealed that SERPINF1 is mainly expressed in dendritic 681 cells, suggesting a potential reduction of these cells within immune-related depression 682 symptom clusters. This finding merits additional exploration, as it could open new pathways 683 for understanding and potentially targeting the immune-related aspects of depression 684 symptoms.

685

Our study has some limitations worth noting. Firstly, the heterogeneity of our sample, which includes a transdiagnostic sample of both in- and out-patients with varying medication usage and comorbid conditions, may affect the generalizability of our findings. Secondly, the imaging and psychophysiology data represents a proportion of the total samples (63%), which requires caution in interpretation of these findings. Additionally, the cell type composition in our study was inferred from the RNA-seg data rather than being directly measured, which could impact the accuracy of these estimates. As there was no validation
sample, these limitations underscore the importance of further research to validate and
expand our findings.

695

696 Taken together, our multi-omics integration analysis successfully discovered two clusters 697 with immune-related depression symptoms, supporting the immuno-metabolic depression 698 hypothesis and highlighting the importance of biological variables such as age and BMI. 699 Incorporating single cell data, we uncovered cell type specific inflammation dysregulation 700 involving SERPINF1 and VEGF-A, both previously implicated in depression. This integrated 701 approach, recognizing depression's heterogeneity, enhances our understanding of its 702 complexity by exploring symptoms across diagnoses. It highlights novel immune markers 703 and genes as potential targets for clinical stratification and new therapeutic intervention.

# 704 References

705 Arias, Daniel, Shekhar Saxena, and Stéphane Verguet. 2022. "Quantifying the Global

706 Burden of Mental Disorders and Their Economic Value." *eClinicalMedicine* 54

707 (December). https://doi.org/10.1016/j.eclinm.2022.101675.

708 Attia, Mikaël, Christophe Rachez, Antoine De Pauw, Philip Avner, and Ute Christine Rogner.

709 2007. "Nap1I2 Promotes Histone Acetylation Activity during Neuronal Differentiation."

710 *Molecular and Cellular Biology* 27 (17): 6093. https://doi.org/10.1128/MCB.00789-07.

711 Barnes, Jacob, Valeria Mondelli, and Carmine M. Pariante. 2017. "Genetic Contributions of

712 Inflammation to Depression." *Neuropsychopharmacology* 42 (1): 81–98.

713 https://doi.org/10.1038/npp.2016.169.

Baune, Bernhard T., Emma Sampson, Jennie Louise, Hikaru Hori, K. Oliver Schubert, Scott
 R. Clark, Natalie T. Mills, and Celia Fourrier. 2021. "No Evidence for Clinical Efficacy
 of Adjunctive Celecoxib with Vortioxetine in the Treatment of Depression: A 6-Week

717 Double-Blind Placebo Controlled Randomized Trial." *European* 

- 718 *Neuropsychopharmacology* 53: 34–46.
- 719 Bruckl, T. M., V. I. Spoormaker, P. G. Samann, A. K. Brem, L. Henco, D. Czamara, I. Elbau,
- 720 et al. 2020. "The Biological Classification of Mental Disorders (BeCOME) Study: A
- 721 Protocol for an Observational Deep-Phenotyping Study for the Identification of
- 722 Biological Subtypes." BMC Psychiatry 20 (1): 213. https://doi.org/10.1186/s12888-
- 723 020-02541-z.
- C. Shelton, Richard, and Andrew H. Miller. 2011. "Inflammation in Depression: Is Adiposity a
   Cause?" *Dialogues in Clinical Neuroscience* 13 (1): 41–53.
- 726 https://doi.org/10.31887/DCNS.2011.13.1/rshelton.
- 727 Camacho-Arroyo, Ignacio, Mónica Flores-Ramos, Ismael Mancilla-Herrera, Fausto Moisés
- 728 Coronel Cruz, Joselin Hernández-Ruiz, Gabriela Pellón Diaz, Blanca Farfán
- Labonne, María del Pilar Meza-Rodríguez, and Philippe Leff Gelman. 2021.
- 730 "Chemokine Profile in Women with Moderate to Severe Anxiety and Depression
- during Pregnancy." *BMC Pregnancy and Childbirth* 21 (1): 807.
- 732 https://doi.org/10.1186/s12884-021-04225-2.
- 733 Cattaneo, Annamaria, Clarissa Ferrari, Lorinda Turner, Nicole Mariani, Daniela Enache,
- 734 Caitlin Hastings, Melisa Kose, Giulia Lombardo, Anna P. McLaughlin, and Maria A.
- 735 Nettis. 2020. "Whole-Blood Expression of Inflammasome-and Glucocorticoid-Related
- 736 mRNAs Correctly Separates Treatment-Resistant Depressed Patients from Drug-
- 737 Free and Responsive Patients in the BIODEP Study." *Translational Psychiatry* 10 (1):
- 738 1–14.
- 739 Chae, Woo Ri, Julia Nübel, Jens Baumert, Stefan M. Gold, and Christian Otte. 2022.
- 740 "Association of Depression and Obesity with C-Reactive Protein in Germany: A Large
- 741 Nationally Representative Study." *Brain, Behavior, and Immunity* 103 (July): 223–31.
- 742 https://doi.org/10.1016/j.bbi.2022.04.024.
- 743 Chamberlain, Samuel R., Jonathan Cavanagh, Peter de Boer, Valeria Mondelli, Declan N. C.
- Jones, Wayne C. Drevets, Philip J. Cowen, et al. 2019. "Treatment-Resistant
- 745 Depression and Peripheral C-Reactive Protein." *The British Journal of Psychiatry* 214

- 746 (1): 11–19. https://doi.org/10.1192/bjp.2018.66.
- 747 Cho, J. H., M. R. Irwin, N. I. Eisenberger, D. M. Lamkin, and S. W. Cole. 2019.
- 748 "Transcriptomic Predictors of Inflammation-Induced Depressed Mood."
- 749 *Neuropsychopharmacology* 44 (5): 923–29. https://doi.org/10.1038/s41386-019-
- 750 0316-9.
- 751 Dawson, D. W., O. V. Volpert, P. Gillis, S. E. Crawford, H.-J. Xu, W. Benedict, and N. P.
- 752 Bouck. 1999. "Pigment Epithelium-Derived Factor: A Potent Inhibitor of
- 753 Angiogenesis." *Science* 285 (5425): 245–48.
- 754 https://doi.org/10.1126/science.285.5425.245.
- 755 De Falco, Sandro. 2012. "The Discovery of Placenta Growth Factor and Its Biological
- 756 Activity." *Experimental & Molecular Medicine* 44 (1): 1–9.
- 757 https://doi.org/10.3858/emm.2012.44.1.025.
- 758 Dell'Acqua, Carola, Elisa Dal Bò, Simone Messerotti Benvenuti, and Daniela Palomba. 2020.
- 759 "Reduced Heart Rate Variability Is Associated with Vulnerability to Depression."
- *Journal of Affective Disorders Reports* 1 (December): 100006.
- 761 https://doi.org/10.1016/j.jadr.2020.100006.
- 762 Dobin, Alexander, Carrie A. Davis, Felix Schlesinger, Jorg Drenkow, Chris Zaleski, Sonali
- 763 Jha, Philippe Batut, Mark Chaisson, and Thomas R. Gingeras. 2013. "STAR:
- 764 Ultrafast Universal RNA-Seq Aligner." *Bioinformatics* 29 (1): 15–21.
- 765 https://doi.org/10.1093/bioinformatics/bts635.
- 766 Drevets, Wayne C., Gayle M. Wittenberg, Edward T. Bullmore, and Husseini K. Manji. 2022.
- 767 "Immune Targets for Therapeutic Development in Depression: Towards Precision
- 768 Medicine." *Nature Reviews Drug Discovery* 21 (3): 224–44.
- 769 https://doi.org/10.1038/s41573-021-00368-1.
- Eyre, Harris A., Tracy Air, Alyssa Pradhan, James Johnston, Helen Lavretsky, Michael J.
- 771 Stuart, and Bernhard T. Baune. 2016. "A Meta-Analysis of Chemokines in Major
- 772 Depression." Progress in Neuro-Psychopharmacology & Biological Psychiatry 68
- 773 (July): 1–8. https://doi.org/10.1016/j.pnpbp.2016.02.006.

- Fain, John N. 2006. "Release of Interleukins and Other Inflammatory Cytokines by Human
- Adipose Tissue Is Enhanced in Obesity and Primarily Due to the Nonfat Cells." In
- 776 *Vitamins & Hormones*, 74:443–77. Interleukins. Academic Press.
- 777 https://doi.org/10.1016/S0083-6729(06)74018-3.
- Felger, J. C., Z. Li, E. Haroon, B. J. Woolwine, M. Y. Jung, X. Hu, and A. H. Miller. 2016.
- 779 "Inflammation Is Associated with Decreased Functional Connectivity within
- 780 Corticostriatal Reward Circuitry in Depression." Molecular Psychiatry 21 (10): 1358–
- 781 65. https://doi.org/10.1038/mp.2015.168.
- Figueroa-Hall, Leandra K., Bohan Xu, Rayus Kuplicki, Bart N. Ford, Kaiping Burrows, T.
- 783 Kent Teague, Sandip Sen, et al. 2022. "Psychiatric Symptoms Are Not Associated
- 784 with Circulating CRP Concentrations after Controlling for Medical, Social, and
- 785 Demographic Factors." *Translational Psychiatry* 12 (1): 1–12.
- 786 https://doi.org/10.1038/s41398-022-02049-y.
- 787 Fischl, Bruce. 2012. "FreeSurfer." *NeuroImage* 62 (2): 774–81.
- 788 https://doi.org/10.1016/j.neuroimage.2012.01.021.
- Foley, Éimear M., Joel T. Parkinson, Ruth E. Mitchell, Lorinda Turner, and Golam M.
- 790 Khandaker. 2022. "Peripheral Blood Cellular Immunophenotype in Depression: A
- 791 Systematic Review and Meta-Analysis." *Molecular Psychiatry*, 1–16.
- Franklyn, Sabina I., Jayme Stewart, Cecile Beaurepaire, Emily Thaw, and Robyn J.
- 793 McQuaid. 2022. "Developing Symptom Clusters: Linking Inflammatory Biomarkers to
- 794 Depressive Symptom Profiles." *Translational Psychiatry* 12 (1): 1–7.
- 795 Friedman, Jerome, Trevor Hastie, Rob Tibshirani, Balasubramanian Narasimhan, Kenneth
- Tay, Noah Simon, Junyang Qian, and James Yang. 2023. "Glmnet: Lasso and
- 797 Elastic-Net Regularized Generalized Linear Models." https://cran.r-
- 798 project.org/web/packages/glmnet/index.html.
- 799 Haapakoski, R., J. Mathieu, K. P. Ebmeier, H. Alenius, and M. Kivimaki. 2015. "Cumulative
- 800 Meta-Analysis of Interleukins 6 and 1beta, Tumour Necrosis Factor Alpha and C-
- 801 Reactive Protein in Patients with Major Depressive Disorder." Brain Behav Immun 49

802 (October): 206–15. https://doi.org/10.1016/j.bbi.2015.06.001.

- 803 Halaris, Angelos, Karl Bechter, Ebrahim Haroon, Brain E. Leonard, Andrew Miller, Carmine
- 804 Pariante, and Patricia Zunszain. 2019. "The Future of Psychoneuroimmunology:
- 805 Promises and Challenges." In Advances in Psychiatry, edited by Afzal Javed and
- 806 Kostas N. Fountoulakis, 235–66. Cham: Springer International Publishing.
- 807 https://doi.org/10.1007/978-3-319-70554-5\_15.
- 808 Hammen, Constance L. 2015. "Stress and Depression: Old Questions, New Approaches."
- 809 *Current Opinion in Psychology*, Depression, 4 (August): 80–85.
- 810 https://doi.org/10.1016/j.copsyc.2014.12.024.

Hänzelmann, Sonja, Robert Castelo, and Justin Guinney. 2013. "GSVA: Gene Set Variation
Analysis for Microarray and RNA-Seq Data." *BMC Bioinformatics* 14: 1–15.

813 Hartmann, Ralf, Frank M. Schmidt, Christian Sander, and Ulrich Hegerl. 2019. "Heart Rate

814 Variability as Indicator of Clinical State in Depression." *Frontiers in Psychiatry* 9.

815 https://www.frontiersin.org/articles/10.3389/fpsyt.2018.00735.

816 Hautzinger, Martin, Ferdinand Keller, and Christine Kühner. 2006. "BDI-II. Das Beck

817 Depressions-Inventar II. Revision." Pearson Deutschland.

818 Hellmann-Regen, Julian, Vera Clemens, Michael Grözinger, Johannes Kornhuber, Andreas

- 819 Reif, David Prvulovic, Roberto Goya-Maldonado, et al. 2022. "Effect of Minocycline
- 820 on Depressive Symptoms in Patients With Treatment-Resistant Depression: A

821 Randomized Clinical Trial." *JAMA Network Open* 5 (9): e2230367.

https://doi.org/10.1001/jamanetworkopen.2022.30367.

823 Herman, James P., Jessica M. McKlveen, Sriparna Ghosal, Brittany Kopp, Aynara Wulsin,

- 824 Ryan Makinson, Jessie Scheimann, and Brent Myers. 2016. "Regulation of the
- 825 Hypothalamic-Pituitary-Adrenocortical Stress Response." *Comprehensive Physiology*
- 826 6 (2): 603–21. https://doi.org/10.1002/cphy.c150015.
- Hibar, D P, L T Westlye, T G M van Erp, J Rasmussen, C D Leonardo, J Faskowitz, U K
- 828 Haukvik, et al. 2016. "Subcortical Volumetric Abnormalities in Bipolar Disorder."
- 829 *Molecular Psychiatry* 21 (12): 1710–16. https://doi.org/10.1038/mp.2015.227.

Horn, Sarah R., Madison M. Long, Benjamin W. Nelson, Nicholas B. Allen, Philip A. Fisher,

- and Michelle L. Byrne. 2018. "Replication and Reproducibility Issues in the
- 832 Relationship between C-Reactive Protein and Depression: A Systematic Review and
- 833 Focused Meta-Analysis." *Brain, Behavior, and Immunity* 73 (October): 85–114.
- 834 https://doi.org/10.1016/j.bbi.2018.06.016.
- 835 Howard, David M., Mark J. Adams, Toni-Kim Clarke, Jonathan D. Hafferty, Jude Gibson,
- 836 Masoud Shirali, Jonathan R. I. Coleman, et al. 2019. "Genome-Wide Meta-Analysis
- of Depression Identifies 102 Independent Variants and Highlights the Importance of
- the Prefrontal Brain Regions." *Nature Neuroscience* 22 (3): 343–52.
- 839 https://doi.org/10.1038/s41593-018-0326-7.
- 840 Husain, Muhammad Ishrat, Imran B. Chaudhry, Ameer B. Khoso, Muhammad Omair Husain,
- John Hodsoll, Moin A. Ansari, Haider A. Naqvi, et al. 2020. "Minocycline and
- 842 Celecoxib as Adjunctive Treatments for Bipolar Depression: A Multicentre, Factorial
- B43 Design Randomised Controlled Trial." *The Lancet Psychiatry* 7 (6): 515–27.
- 844 https://doi.org/10.1016/S2215-0366(20)30138-3.
- Janelidze, Shorena, Filip Ventorp, Sophie Erhardt, Oskar Hansson, Lennart Minthon, John
- 846 Flax, Martin Samuelsson, Lil Traskman-Bendz, and Lena Brundin. 2013. "Altered
- 847 Chemokine Levels in the Cerebrospinal Fluid and Plasma of Suicide Attempters."
- 848 Psychoneuroendocrinology 38 (6): 853–62.
- 849 https://doi.org/10.1016/j.psyneuen.2012.09.010.
- 850 Kappelmann, Nils, Janine Arloth, Marios K. Georgakis, Darina Czamara, Nicolas Rost,
- 851 Symen Ligthart, Golam M. Khandaker, and Elisabeth B. Binder. 2021. "Dissecting the
- Association Between Inflammation, Metabolic Dysregulation, and Specific
- 853 Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian
- 854 Randomization Study." *JAMA Psychiatry* 78 (2): 161–70.
- https://doi.org/10.1001/jamapsychiatry.2020.3436.
- 856 Kaufman, Joan, and Dennis Charney. 2000. "Comorbidity of Mood and Anxiety Disorders."
- 857 Depression and Anxiety 12 (S1): 69–76. https://doi.org/10.1002/1520-

858 6394(2000)12:1+<69::AID-DA9>3.0.CO;2-K.

- 859 Kessler, R. C., H. M. van Loo, K. J. Wardenaar, R. M. Bossarte, L. A. Brenner, D. D. Ebert, 860 P. de Jonge, et al. 2017. "Using Patient Self-Reports to Study Heterogeneity of 861 Treatment Effects in Major Depressive Disorder." Epidemiology and Psychiatric 862 Sciences 26 (1): 22-36. https://doi.org/10.1017/S2045796016000020. 863 Koch, Celine, Marcel Wilhelm, Stefan Salzmann, Winfried Rief, and Frank Euteneuer, 2019. 864 "A Meta-Analysis of Heart Rate Variability in Major Depression." Psychological 865 Medicine 49 (12): 1948–57. https://doi.org/10.1017/S0033291719001351. 866 Köhler-Forsberg, O., C. N. Lydholm, C. Hjorthøj, M. Nordentoft, O. Mors, and M. E. Benros. 867 2019. "Efficacy of Anti-Inflammatory Treatment on Major Depressive Disorder or 868 Depressive Symptoms: Meta-Analysis of Clinical Trials." Acta Psychiatrica 869 Scandinavica 139 (5): 404–19. https://doi.org/10.1111/acps.13016. 870 Kopf-Beck, Johannes, Petra Zimmermann, Samy Egli, Martin Rein, Nils Kappelmann, Julia 871 Fietz, Jeanette Tamm, Katharina Rek, Susanne Lucae, and Anna-Katharine Brem. 872 2020. "Schema Therapy versus Cognitive Behavioral Therapy versus Individual 873 Supportive Therapy for Depression in an Inpatient and Day Clinic Setting: Study 874 Protocol of the OPTIMA-RCT." BMC Psychiatry 20: 1-19. 875 Kriegeskorte, Nikolaus, W. Kyle Simmons, Patrick S. F. Bellgowan, and Chris I. Baker. 2009. 876 "Circular Analysis in Systems Neuroscience: The Dangers of Double Dipping." Nature Neuroscience 12 (5): 535-40. https://doi.org/10.1038/nn.2303. 877 878 Kurolap, Alina, Florian Kreuder, Claudia Gonzaga-Jauregui, Morasha Plesser Duvdevani, 879 Tamar Harel, Luna Tammer, Baozhong Xin, et al. 2022. "Bi-Allelic Variants in 880 Neuronal Cell Adhesion Molecule Cause a Neurodevelopmental Disorder 881 Characterized by Developmental Delay, Hypotonia, Neuropathy/Spasticity." 882 American Journal of Human Genetics 109 (3): 518–32. 883 https://doi.org/10.1016/j.ajhg.2022.01.004. 884 Lamers, F., Y. Milaneschi, C. H. Vinkers, R. A. Schoevers, E. J. Giltay, and Bwjh Penninx.
- 885 2020. "Depression Profilers and Immuno-Metabolic Dysregulation: Longitudinal

886 Results from the NESDA Study." *Brain Behav Immun* 88 (August): 174–83.

887 https://doi.org/10.1016/j.bbi.2020.04.002.

- Lamers, F., N. Vogelzangs, K. R. Merikangas, P. de Jonge, A. T. F. Beekman, and B. W. J.
- 889 H. Penninx. 2013. "Evidence for a Differential Role of HPA-Axis Function,
- 890 Inflammation and Metabolic Syndrome in Melancholic versus Atypical Depression."

891 *Molecular Psychiatry* 18 (6): 692–99. https://doi.org/10.1038/mp.2012.144.

- Lasselin, Julie, Manfred Schedlowski, Bianka Karshikoff, Harald Engler, Mats Lekander, and
- 393 Jan Pieter Konsman. 2020. "Comparison of Bacterial Lipopolysaccharide-Induced
- 894 Sickness Behavior in Rodents and Humans: Relevance for Symptoms of Anxiety and
- 895 Depression." *Neuroscience & Biobehavioral Reviews* 115 (August): 15–24.
- 896 https://doi.org/10.1016/j.neubiorev.2020.05.001.
- 897 Leek, Jeffrey T., W. Evan Johnson, Hilary S. Parker, Elana J. Fertig, Andrew E. Jaffe,
- Yuqing Zhang, John D. Storey, and Leonardo Collado Torres. 2021. "Sva: Surrogate
  Variable Analysis." Bioconductor version: 3.12. https://doi.org/10.18129/B9.bioc.sva.
- 900 Leighton, S. P., L. Nerurkar, R. Krishnadas, C. Johnman, G. J. Graham, and J. Cavanagh.

901 2018. "Chemokines in Depression in Health and in Inflammatory Illness: A

- 902 Systematic Review and Meta-Analysis." *Molecular Psychiatry* 23 (1): 48–58.
- 903 https://doi.org/10.1038/mp.2017.205.
- Li, Yunjin, Lu Ma, Duojiao Wu, and Geng Chen. 2021. "Advances in Bulk and Single-Cell
   Multi-Omics Approaches for Systems Biology and Precision Medicine." *Briefings in*

906 Bioinformatics 22 (5): bbab024. https://doi.org/10.1093/bib/bbab024.

Liao, Yang, Gordon K. Smyth, and Wei Shi. 2014. "featureCounts: An Efficient General

908 Purpose Program for Assigning Sequence Reads to Genomic Features."

- Bioinformatics 30 (7): 923–30. https://doi.org/10.1093/bioinformatics/btt656.
- 910 Lijnen, H. Roger, Valerie Christiaens, Ilse Scroyen, Gabor Voros, Marc Tjwa, Peter
- 911 Carmeliet, and Désiré Collen. 2006. "Impaired Adipose Tissue Development in Mice
- 912 With Inactivation of Placental Growth Factor Function." *Diabetes* 55 (10): 2698–2704.
- 913 https://doi.org/10.2337/db06-0526.

914 Love, Michael, Constantin Ahlmann-Eltze, Kwame Forbes, Simon Anders, and Wolfgang

- 915 Huber. 2021. "DESeq2: Differential Gene Expression Analysis Based on the
- 916 Negative Binomial Distribution." Bioconductor version: 3.12.
- 917 https://doi.org/10.18129/B9.bioc.DESeq2.
- 918 Lucido, Michael J., Mandy Bekhbat, David R. Goldsmith, Michael T. Treadway, Ebrahim
- 919 Haroon, Jennifer C. Felger, and Andrew H. Miller. 2021. "Aiding and Abetting
- 920 Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications."
  921 *Pharmacological Reviews* 73 (3): 1084–1117.
- 922 Lynall, M. E., L. Turner, J. Bhatti, J. Cavanagh, P. de Boer, V. Mondelli, D. Jones, et al.

923 2020. "Peripheral Blood Cell-Stratified Subgroups of Inflamed Depression." *Biol*924 *Psychiatry* 88 (2): 185–96. https://doi.org/10.1016/j.biopsych.2019.11.017.

- 925 Martin, Fergal J, M Ridwan Amode, Alisha Aneja, Olanrewaju Austine-Orimoloye, Andrey G
- Azov, If Barnes, Arne Becker, et al. 2023. "Ensembl 2023." *Nucleic Acids Research*51 (D1): D933–41. https://doi.org/10.1093/nar/gkac958.

McGuffin, Peter, Randy Katz, Sarah Watkins, and Joan Rutherford. 1996. "A Hospital-Based
 Twin Register of the Heritability of DSM-IV Unipolar Depression." *Archives of General Psychiatry* 53 (2): 129–36. https://doi.org/10.1001/archpsyc.1996.01830020047006.

930 *Psychiatry* 53 (2): 129–36. https://doi.org/10.1001/archpsyc.1996.01830020047006.

- 931 Mehta, Divya, Charles L. Raison, Bobbi J. Woolwine, Ebrahim Haroon, Elisabeth B. Binder,
- Andrew H. Miller, and Jennifer C. Felger. 2013. "Transcriptional Signatures Related
- 933 to Glucose and Lipid Metabolism Predict Treatment Response to the Tumor Necrosis
- 934 Factor Antagonist Infliximab in Patients with Treatment-Resistant Depression." Brain,
- 935 *Behavior, and Immunity*, Inflammation and Mental Health, 31 (July): 205–15.
- 936 https://doi.org/10.1016/j.bbi.2013.04.004.
- 937 Mengelkoch, Summer, Ziv Lautman, Jenna C. Alley, Lydia G. Roos, Benjamin Ehlert, Daniel
- 938 P. Moriarity, Samuel Lancaster, Sophia Miryam Schüssler-Fiorenza Rose, Michael P.
- 939 Snyder, and George M. Slavich. 2023. "Multi-Omics Approaches in
- 940 Psychoneuroimmunology and Health Research: Conceptual Considerations and
- 941 Methodological Recommendations." *Brain, Behavior, and Immunity*, August.

942 https://doi.org/10.1016/j.bbi.2023.07.022.

- 943 Milaneschi, Yuri, Anna Maria Corsi, Brenda W. Penninx, Stefania Bandinelli, Jack M.
- 944 Guralnik, and Luigi Ferrucci. 2009. "Interleukin-1 Receptor Antagonist and Incident
- 945 Depressive Symptoms Over 6 Years in Older Persons: The InCHIANTI Study."
- 946 *Biological Psychiatry*, Stress, Aging, and Alzheimer's Disease, 65 (11): 973–78.
- 947 https://doi.org/10.1016/j.biopsych.2008.11.011.
- 948 Milaneschi, Yuri, Femke Lamers, Michael Berk, and Brenda WJH Penninx. 2020.
- 949 "Depression Heterogeneity and Its Biological Underpinnings: Toward
- 950 Immunometabolic Depression." *Biological Psychiatry*.
- 951 Miller, A. H., and C. L. Raison. 2016. "The Role of Inflammation in Depression: From
- 952 Evolutionary Imperative to Modern Treatment Target." *Nat Rev Immunol* 16 (1): 22–
- 953 34. https://doi.org/10.1038/nri.2015.5.
- Miller, Andrew H., and Charles L. Raison. 2023. "Burning down the House: Reinventing Drug
   Discovery in Psychiatry for the Development of Targeted Therapies." *Molecular Psychiatry* 28 (1): 68–75. https://doi.org/10.1038/s41380-022-01887-y.
- 957 Moriarity, Daniel P., Summer Mengelkoch, and George M. Slavich. 2023. "Incorporating
- 958 Causal Inference Perspectives into Psychoneuroimmunology: A Simulation Study
- 959 Highlighting Concerns about Controlling for Adiposity in Immunopsychiatry." *Brain,*
- 960 Behavior, and Immunity 113 (October): 259–66.
- 961 https://doi.org/10.1016/j.bbi.2023.06.022.
- 962 Moshe, Isaac, Yannik Terhorst, Kennedy Opoku Asare, Lasse Bosse Sander, Denzil
- 963 Ferreira, Harald Baumeister, David C. Mohr, and Laura Pulkki-Råback. 2021.
- 964 "Predicting Symptoms of Depression and Anxiety Using Smartphone and Wearable
- 965 Data." *Frontiers in Psychiatry* 12.
- 966 https://www.frontiersin.org/articles/10.3389/fpsyt.2021.625247.
- 967 Nettis, Maria Antonietta, Giulia Lombardo, Caitlin Hastings, Zuzanna Zajkowska, Nicole
- 968 Mariani, Naghmeh Nikkheslat, Courtney Worrell, Daniela Enache, Anna McLaughlin,
- and Melisa Kose. 2021. "Augmentation Therapy with Minocycline in Treatment-

970	Resistant Depression Patients with Low-Grade Peripheral Inflammation: Results from
971	a Double-Blind Randomised Clinical Trial." Neuropsychopharmacology 46 (5): 939–
972	48.
973	O'Donnell, Patricio, Laura Rosen, Robert Alexander, Venkatesha Murthy, Ceri H Davies, and
974	Emiliangelo Ratti. 2019. "Strategies to Address Challenges in Neuroscience Drug
975	Discovery and Development." International Journal of Neuropsychopharmacology 22
976	(7): 445–48. https://doi.org/10.1093/ijnp/pyz027.
977	O'Dushlaine, Colm, Lizzy Rossin, Phil H Lee, Laramie Duncan, Neelroop N Parikshak,
978	Stephen Newhouse, Stephan Ripke, et al. 2015. "Psychiatric Genome-Wide
979	Association Study Analyses Implicate Neuronal, Immune and Histone Pathways."
980	Nature Neuroscience 18 (2): 199–209. https://doi.org/10.1038/nn.3922.
981	Osimo, Emanuele F., Toby Pillinger, Irene Mateos Rodriguez, Golam M. Khandaker,
982	Carmine M. Pariante, and Oliver D. Howes. 2020. "Inflammatory Markers in
983	Depression: A Meta-Analysis of Mean Differences and Variability in 5,166 Patients
984	and 5,083 Controls." Brain, Behavior, and Immunity 87 (July): 901–9.
985	https://doi.org/10.1016/j.bbi.2020.02.010.
986	Osimo, Emanuele Felice, Luke James Baxter, Glyn Lewis, Peter B. Jones, and Golam M.
987	Khandaker. 2019. "Prevalence of Low-Grade Inflammation in Depression: A
988	Systematic Review and Meta-Analysis of CRP Levels." Psychological Medicine 49
989	(12): 1958–70.
990	Oura, Hajimu, Jennifer Bertoncini, Paula Velasco, Lawrence F. Brown, Peter Carmeliet, and
991	Michael Detmar. 2003. "A Critical Role of Placental Growth Factor in the Induction of

- 992 Inflammation and Edema Formation." *Blood* 101 (2): 560–67.
- 993 https://doi.org/10.1182/blood-2002-05-1516.
- 994 Pfister, Sabina, Vincent Kuettel, and Enrico Ferrero. 2023. "Granulator: Rapid Benchmarking
- 995 of Methods for \*in Silico\* Deconvolution of Bulk RNA-Seq Data." Bioconductor

996 version: 3.16. https://doi.org/10.18129/B9.bioc.granulator.

997 R Core Team. 2023. "R: A Language and Environent for Statistical Computing." Vienna,

- 998 Austria: R Foundation for Statistical Computing. https://www.R-project.org/.
- 999 Rohleder, Nicolas. 2019. "Stress and Inflammation The Need to Address the Gap in the
- 1000 Transition between Acute and Chronic Stress Effects." *Psychoneuroendocrinology*,
- 1001 Festschrift for Dirk Hellhammer, 105 (July): 164–71.
- 1002 https://doi.org/10.1016/j.psyneuen.2019.02.021.
- 1003 Ryan, K. M., A. Glaviano, S. M. O'Donovan, E. Kolshus, R. Dunne, A. Kavanagh, A. Jelovac,
- 1004 et al. 2017. "Electroconvulsive Therapy Modulates Plasma Pigment Epithelium-
- 1005 Derived Factor in Depression: A Proteomics Study." *Translational Psychiatry* 7 (3):
- 1006 e1073–e1073. https://doi.org/10.1038/tp.2017.51.
- 1007 Savitz, Jonathan B., T. Kent Teague, Masaya Misaki, Matt Macaluso, Brent E. Wurfel, Matt
- 1008 Meyer, Douglas Drevets, et al. 2018. "Treatment of Bipolar Depression with
- 1009 Minocycline and/or Aspirin: An Adaptive, 2×2 Double-Blind, Randomized, Placebo-
- 1010 Controlled, Phase IIA Clinical Trial." *Translational Psychiatry* 8 (1): 1–11.
- 1011 https://doi.org/10.1038/s41398-017-0073-7.
- 1012 Savitz, Jonathan, Mark Barton Frank, Teresa Victor, Melissa Bebak, Julie H. Marino, Patrick
- 1013 S. F. Bellgowan, Brett A. McKinney, Jerzy Bodurka, T. Kent Teague, and Wayne C.
- 1014 Drevets. 2013. "Inflammation and Neurological Disease-Related Genes Are
- 1015 Differentially Expressed in Depressed Patients with Mood Disorders and Correlate
- 1016 with Morphometric and Functional Imaging Abnormalities." *Brain, Behavior, and*
- 1017 *Immunity* 31 (July): 161–71. https://doi.org/10.1016/j.bbi.2012.10.007.
- 1018 Schmaal, L., D. P. Hibar, P. G. Sämann, G. B. Hall, B. T. Baune, N. Jahanshad, J. W.
- 1019 Cheung, et al. 2017. "Cortical Abnormalities in Adults and Adolescents with Major
- 1020 Depression Based on Brain Scans from 20 Cohorts Worldwide in the ENIGMA Major
- 1021 Depressive Disorder Working Group." *Molecular Psychiatry* 22 (6): 900–909.
- 1022 https://doi.org/10.1038/mp.2016.60.
- 1023 Schmaal, L., D. J. Veltman, T. G. M. van Erp, P. G. Sämann, T. Frodl, N. Jahanshad, E.
- 1024 Loehrer, et al. 2016. "Subcortical Brain Alterations in Major Depressive Disorder:
- 1025 Findings from the ENIGMA Major Depressive Disorder Working Group." *Molecular*

1026 *Psychiatry* 21 (6): 806–12. https://doi.org/10.1038/mp.2015.69.

- 1027 Schmid, Katharina T., Barbara Höllbacher, Cristiana Cruceanu, Anika Böttcher, Heiko
- 1028
   Lickert, Elisabeth B. Binder, Fabian J. Theis, and Matthias Heinig. 2021. "scPower
- 1029Accelerates and Optimizes the Design of Multi-Sample Single Cell Transcriptomic
- 1030 Studies." *Nature Communications* 12 (1): 6625. https://doi.org/10.1038/s41467-021-
- 1031 26779-7.
- 1032Schmidtke, A, P Fleckenstein, W Moises, and H Beckmann. 1988. "Studies of the reliability1033and validity of the German version of the Montgomery-Asberg Depression Rating
- 1034 Scale (MADRS)." Schweizer Archiv fur Neurologie und Psychiatrie (Zurich,
- 1035 *Switzerland* 139 (2): 51–65.
- 1036 Seppälä, Jussi, Ilaria De Vita, Timo Jämsä, Jouko Miettunen, Matti Isohanni, Katya
- 1037Rubinstein, Yoram Feldman, et al. 2019. "Mobile Phone and Wearable Sensor-Based1038mHealth Approaches for Psychiatric Disorders and Symptoms: Systematic Review."
- 1039 *JMIR Mental Health* 6 (2): e9819. https://doi.org/10.2196/mental.9819.
- 1040 Sforzini, Luca, Annamaria Cattaneo, Clarissa Ferrari, Lorinda Turner, Nicole Mariani,
- 1041 Daniela Enache, Caitlin Hastings, Giulia Lombardo, Maria A. Nettis, and Naghmeh
- 1042 Nikkheslat. 2023. "Higher Immune-Related Gene Expression in Major Depression Is
- 1043 Independent of CRP Levels: Results from the BIODEP Study." *Translational*
- 1044 *Psychiatry* 13 (1): 185.
- 1045 Shelton, Richard C., Michael Falola, Li Li, John Zajecka, Maurizio Fava, and George I.
- 1046 Papakostas. 2015. "The Pro-Inflammatory Profile of Depressed Patients Is (Partly)
- 1047 Related to Obesity." *Journal of Psychiatric Research* 70 (November): 91–97.
- 1048 https://doi.org/10.1016/j.jpsychires.2015.09.001.
- 1049 Sienkiewicz, Karolina, Jinyu Chen, Ajay Chatrath, John T. Lawson, Nathan C. Sheffield,
- Louxin Zhang, and Aakrosh Ratan. 2022. "Detecting Molecular Subtypes from MultiOmics Datasets Using SUMO." *Cell Reports Methods*, 100152.
- Simmons, W. Kyle, Kaiping Burrows, Jason A. Avery, Kara L. Kerr, Ashlee Taylor, Jerzy
  Bodurka, William Potter, T. Kent Teague, and Wayne C. Drevets. 2020. "Appetite

- 1054 Changes Reveal Depression Subgroups with Distinct Endocrine, Metabolic, and
- 1055 Immune States." *Molecular Psychiatry* 25 (7): 1457–68.
- 1056 Sørensen, Nina Vindegaard, Nis Borbye-Lorenzen, Rune Haubo Bojesen Christensen,
- 1057 Sonja Orlovska-Waast, Rose Jeppesen, Kristin Skogstrand, and Michael Eriksen
- 1058 Benros. 2023. "Comparisons of 25 Cerebrospinal Fluid Cytokines in a Case–Control
- 1059 Study of 106 Patients with Recent-Onset Depression and 106 Individually Matched
- 1060 Healthy Subjects." *Journal of Neuroinflammation* 20 (1): 1–11.
- 1061 Strawbridge, R., D. Arnone, A. Danese, A. Papadopoulos, A. Herane Vives, and A.J. Cleare.
- 1062 2015. "Inflammation and Clinical Response to Treatment in Depression: A Meta-
- 1063 Analysis." *European Neuropsychopharmacology* 25 (10): 1532–43.
- 1064 https://doi.org/10.1016/j.euroneuro.2015.06.007.
- 1065 Tecchio, Cristina, Alessandra Micheletti, and Marco A. Cassatella. 2014. "Neutrophil-Derived
- 1066 Cytokines: Facts Beyond Expression." *Frontiers in Immunology* 5.
- 1067 https://www.frontiersin.org/articles/10.3389/fimmu.2014.00508.
- 1068 The MathWorks Inc. 2020. "MATLAB Version: R2020b." Natick, Massachusetts, United

1069 States: The MathWorks Inc. https://www.mathworks.com.

- 1070 Tian, Tian, Yongtao Yang, Bing Xu, Yinhua Qin, Guangchao Zang, Chanjuan Zhou, Peng
- 1071 Zheng, et al. 2020. "Pigment Epithelium-Derived Factor Alleviates Depressive-like
- 1072 Behaviors in Mice by Modulating Adult Hippocampal Synaptic Growth and Wnt
- 1073 Pathway." Progress in Neuro-Psychopharmacology and Biological Psychiatry 98

1074 (March): 109792. https://doi.org/10.1016/j.pnpbp.2019.109792.

- 1075 Tombran-Tink, Joyce, and Colin J. Barnstable. 2003. "PEDF: A Multifaceted Neurotrophic
- 1076 Factor." *Nature Reviews Neuroscience* 4 (8): 628–36.
- 1077 https://doi.org/10.1038/nrn1176.
- 1078 Torres-Platas, Susana G., Cristiana Cruceanu, Gary Gang Chen, Gustavo Turecki, and
- 1079 Naguib Mechawar. 2014. "Evidence for Increased Microglial Priming and
- 1080 Macrophage Recruitment in the Dorsal Anterior Cingulate White Matter of Depressed
- 1081 Suicides." *Brain, Behavior, and Immunity* 42 (November): 50–59.

1082 https://doi.org/10.1016/j.bbi.2014.05.007.

- 1083 Turner, Cortney A., Robert C. Thompson, William E. Bunney, Alan F. Schatzberg, Jack D.
- 1084 Barchas, Richard M. Myers, Huda Akil, and Stanley J. Watson. 2014. "Altered
- 1085 Choroid Plexus Gene Expression in Major Depressive Disorder." *Frontiers in Human*
- 1086 *Neuroscience* 8. https://www.frontiersin.org/articles/10.3389/fnhum.2014.00238.
- 1087 Vest, Adriana N., Giulia Da Poian, Qiao Li, Chengyu Liu, Shamim Nemati, Amit J. Shah, and
- 1088 Gari D. Clifford. 2018. "An Open Source Benchmarked Toolbox for Cardiovascular
- 1089 Waveform and Interval Analysis." *Physiological Measurement* 39 (10): 105004.
- 1090 https://doi.org/10.1088/1361-6579/aae021.
- 1091 Vos, Theo, Stephen S. Lim, Cristiana Abbafati, Kaja M. Abbas, Mohammad Abbasi, Mitra
- 1092 Abbasifard, Mohsen Abbasi-Kangevari, et al. 2020. "Global Burden of 369 Diseases
- and Injuries in 204 Countries and Territories, 1990–2019: A Systematic Analysis for
- the Global Burden of Disease Study 2019." *The Lancet* 396 (10258): 1204–22.
- 1095 https://doi.org/10.1016/S0140-6736(20)30925-9.
- 1096 Wittchen, H.-U., E. Beloch, E. Garzcynski, A. Holly, G. Lachner, A. Perkonigg, E.-M. Pfütze,
- 1097 et al. 1995. "Münchener Composite International Diagnostic Interview (M-CIDI)
- 1098 (Version 2.2 / 2 / 95)." Max-Planck-Institut für Psychiatrie, Klinisches Institut,
  1099 München.
- Wittchen, H.-U., and H. Pfister. 1997. "DIA-X-Interviews: Manual für Screening-Verfahren
  und Interview; Interviewheft." https://hdl.handle.net/11858/00-001M-0000-000E-
- 1102 AAAF-C.
- 1103 Wittenberg, G. M., J. Greene, P. E. Vertes, W. C. Drevets, and E. T. Bullmore. 2020. "Major
- 1104 Depressive Disorder Is Associated With Differential Expression of Innate Immune
- and Neutrophil-Related Gene Networks in Peripheral Blood: A Quantitative Review of
- 1106 Whole-Genome Transcriptional Data From Case-Control Studies." *Biol Psychiatry* 88
- 1107 (8): 625–37. https://doi.org/10.1016/j.biopsych.2020.05.006.
- Wolf, F. Alexander, Philipp Angerer, and Fabian J. Theis. 2018. "SCANPY: Large-Scale
  Single-Cell Gene Expression Data Analysis." *Genome Biology* 19 (1): 15.

1110 https://doi.org/10.1186/s13059-017-1382-0.

- 1111 Yang, Chenghao, Klaas J. Wardenaar, Fokko J. Bosker, Jie Li, and Robert A. Schoevers.
- 1112 2019. "Inflammatory Markers and Treatment Outcome in Treatment Resistant
- 1113 Depression: A Systematic Review." *Journal of Affective Disorders* 257 (October):
- 1114 640–49. https://doi.org/10.1016/j.jad.2019.07.045.
- 1115 Young, Juan Joseph, Davide Bruno, and Nunzio Pomara. 2014. "A Review of the
- 1116 Relationship between Proinflammatory Cytokines and Major Depressive Disorder."
- 1117 *Journal of Affective Disorders* 169 (December): 15–20.
- 1118 https://doi.org/10.1016/j.jad.2014.07.032.
- 1119 Yue, Yingying, Haitang Jiang, Rui Liu, Yingying Yin, Yuqun Zhang, Jinfeng Liang, Shenghua
- 1120 Li, et al. 2016. "Towards a Multi Protein and mRNA Expression of Biological
- 1121 Predictive and Distinguish Model for Post Stroke Depression." Oncotarget 7 (34):
- 1122 54329–38. https://doi.org/10.18632/oncotarget.11105.

## 1123 Data and Code availability

- 1124 The computational code has been made available on GitHub:
- 1125 https://github.com/cellmapslab/ImmuneDepressionSymptoms, while the RNA-seq data is
- 1126 accessible in the GEO repository under GSE260603 and the immune marker data in the
- 1127 Zenodo repository https://zenodo.org/doi/10.5281/zenodo.10698978.

## 1128 Conflict of interest

- 1129 VIS has provided consulting and advisory services for Roche and Sony. The other authors
- 1130 declare no conflict of interest.

## 1131 Acknowledgments

- 1132 We extend our gratitude to all participants of the BeCOME and OPTIMA studies without
- 1133 whom our research would not be possible. We thank the Biomaterial processing and
- 1134 repository unit (BioPrep) of the Max Planck Institute of Psychiatry for their handling of the
- 1135 biological samples and the RNA isolation.
- 1136 Dr. Knauer-Arloth's contributions were supported by the Brain & Behavior Research
- 1137 Foundation (NARSAD Young Investigator Grant, #28063).
- 1138

## 1139 Contributions

- 1140 Jonas Hagenberg: Conceptualization, Methodology, Software, Formal analysis, Writing -
- 1141 Original Draft, Visualization
- 1142 BeCOME study group: Resources
- 1143 OPTIMA study group: Resources
- 1144 Tanja Brückl: Data curation, Formal analysis, Writing Review & Editing
- 1145 Mira Erhart: Formal analysis, Writing Review & Editing
- 1146 Johannes Kopf-Beck: Data curation, Writing Review & Editing
- 1147 Maik Ködel: Investigation
- 1148 Ghalia Rehawi: Software, Writing Review & Editing
- 1149 Simone Röh-Karamihalev: Software
- 1150 Susann Sauer: Investigation
- 1151 Natan Yusupov: Data curation, Writing Review & Editing
- 1152 Monika Rex-Haffner: Investigation
- 1153 Victor Spoormaker: Supervision, Writing Review & Editing
- 1154 Philipp Sämann: Methodology, Formal Analysis, Writing Review & Editing
- 1155 Elisabeth Binder: Supervision, Funding acquisition, Writing Review & Editing

1156 Janine Knauer-Arloth: Conceptualization, Visualization, Supervision, Funding acquisition,

- 1157 Writing Review & Editing
- 1158

1159 JH processed the immune marker and RNA-seg data, designed and carried out the 1160 clustering and the subsequent analyses, provided critical intellectual input and wrote the 1161 initial manuscript draft; BSG and OSG recruited participants, carried out the studies and 1162 provided data; TMB processed the phenotype data and provided critical intellectual input on 1163 the phenotypes; ME and VIS led the electrocardiography data analysis; JKB provided 1164 phenotype data; MK performed immune marker measurements; GR advised on cell type 1165 deconvolution; SRK advised on RNA-seq data analysis; NY processed phenotype data; 1166 MRH supported experimental procedures and project organization; PS led the imaging data 1167 analysis and contributed to the manuscript draft; EB supervised the project and acquired 1168 funding; JKA conceived the idea, acquired funding, supervised the project, designed 1169 experiments and analyses, provided critical intellectual input and contributed to the 1170 manuscript draft writing.

1171